CYTOKINES AND GROWTH-FACTORS IN ATHEROGENESIS

被引:0
|
作者
CLINTON, SK [1 ]
LIBBY, P [1 ]
机构
[1] BRIGHAM & WOMENS HOSP,DEPT MED,VASC MED & ATHEROSCLEROSIS UNIT,BOSTON,MA 02115
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The development of laboratory techniques for the culturing of vascular endothelial and smooth-muscle cells during the 1970s, followed by the rapid advances in molecular and cell biology during the 1980s, provided the foundation for the identification of growth factor and cytokine networks involved in maintenance of the normal vasculature as well as participating in diverse pathologic processes involving blood vessels.1-3 Vascular cells can produce and respond to a vast array of biochemical messengers that control cell replication, differentiation, and many specific cell functions. Investigators are beginning to explore the changes in the patterns of messengers exchanged between the vascular cells and infiltrating leukocytes during the initiation and progression of atherosclerosis. A variety of in vitro and in vivo studies have indicated that growth factors and cytokines that mediate the critical processes of inflammation and wound healing also play a central role in vascular disease. Indeed, many view atherosclerosis as the result of excessive or prolonged chronic inflammation and wound healing in response to diverse injurious stimuli to cells of the vessel wall. Vascular injury may result from many varied and interacting forces, including nutritional and metabolic abnormalities such as hyperlipidemias or elevated homocysteine, mechanical forces associated with hypertension, exogenous toxins including those found in cigarette smoke, abnormally glycated proteins associated with diabetes mellitus, oxidatively modified lipids or proteins, and, possibly, viral infections. Ultimately, a greater understanding of the activated cytokine and growth factor networks within the vascular wall following injury and during atherogenesis will allow clinical scientists to identify steps susceptible to therapeutic intervention using recombinant cytokines, antibodies, soluble receptors, or receptor antagonists. Other therapeutic strategies may involve the transfection of specific genes, which may inhibit atherosclerosis, into vascular cells at sites prone to lesion formation.
引用
收藏
页码:1292 / 1300
页数:9
相关论文
共 50 条
  • [1] CYTOKINES AND GROWTH-FACTORS IN IMPLANTATION
    HAIMOVICI, F
    ANDERSON, DJ
    MICROSCOPY RESEARCH AND TECHNIQUE, 1993, 25 (03) : 201 - 207
  • [2] CYTOKINES, GROWTH-FACTORS AND INFLAMMATION
    PUJOL, JP
    REVUE DU RHUMATISME, 1988, 55 (06): : 430 - 434
  • [3] CYTOKINES AND GROWTH-FACTORS - FOREWORD
    BRENNER, MK
    BAILLIERES CLINICAL HAEMATOLOGY, 1994, 7 (01): : R9 - R10
  • [4] ENDOTHELIAL-CELL GROWTH-FACTORS IN ATHEROGENESIS
    HOOVER, GA
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1990, 143 (10) : 1035 - 1035
  • [5] HYBRID CYTOKINES AS HEMATOPOIETIC GROWTH-FACTORS
    WILLIAMS, DE
    PARK, LS
    BROXMEYER, HE
    LU, L
    INTERNATIONAL JOURNAL OF CELL CLONING, 1991, 9 (06): : 542 - 547
  • [6] CYTOKINES AND GROWTH-FACTORS IN RENAL INJURY
    SEDOR, JR
    SEMINARS IN NEPHROLOGY, 1992, 12 (05) : 428 - 440
  • [7] CYTOKINES AND GROWTH-FACTORS IN ENDOTHELIAL DYSFUNCTION
    LEFER, AM
    MA, XL
    CRITICAL CARE MEDICINE, 1993, 21 (02) : S9 - S14
  • [8] CYTOKINES AS AUTOCRINE GROWTH-FACTORS IN MALIGNANCIES
    KAWANO, M
    KURAMOTO, A
    HIRANO, T
    KISHIMOTO, T
    CANCER SURVEYS, 1989, 8 (04) : 905 - 919
  • [9] GROWTH-FACTORS, CYTOKINES, AND VASCULAR INJURY
    FAGIN, JA
    FORRESTER, JS
    TRENDS IN CARDIOVASCULAR MEDICINE, 1992, 2 (03) : 90 - 94
  • [10] BIOLOGICAL POTENCY STANDARDS FOR CYTOKINES AND GROWTH-FACTORS
    GERRARD, TL
    THORPE, R
    JEFFCOATE, S
    REYNOLDS, C
    BIOLOGICALS, 1993, 21 (01) : 77 - 79